The raised guidance and strong revenue growth across most segments suggest accelerating adoption of AtriCure's core products. Monitor the BoxX-NoAF and LeAAPS clinical trial readouts for potential catalysts, and watch the minimally invasive ablation decline for competitive pressure from PFA catheters.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $65.53entry
- T+1 · 12d ago −6.49%α −2.08% · $61.28
- T+5 · 6d ago −12.21%α −11.30% · $57.53
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AtriCure reported Q3 2026 revenue of $154.5M (+15.0% YoY), beating the $151.2M consensus, and GAAP EPS of $0.08, beating the $0.01 consensus. The company raised its full-year 2026 revenue guidance to $606M-$610M and adjusted EBITDA guidance to $91M-$94M, signaling continued operational momentum.
Key Financial Metrics
Key Facts
- Q3 2026 worldwide revenue of $154.5M, up 15.0% YoY (15.1% constant currency)
- GAAP net income of $4.1M vs. a loss of $0.3M in Q3 2025
- GAAP diluted EPS of $0.08 vs. ($0.01) in Q3 2025
- Adjusted EBITDA of $26.8M, up 51% YoY from $17.8M
- Adjusted EPS of $0.18 vs. ($0.01) in Q3 2025
- Full-year 2026 revenue guidance raised to $606M-$610M (from $602M-$610M)
- Full-year 2026 adjusted EBITDA guidance raised to $91M-$94M (from $85M-$89M)
- U.S. revenue grew 17.1% to $128.0M; pain management revenue up 34.7% to $28.1M
- Minimally invasive ablation revenue declined to $5.4M from $7.4M due to PFA catheter adoption
Financial Impact
Revenue beat consensus by $3.3M (2.2%); EPS beat consensus by $0.07 (700%); guidance raised for both revenue and adjusted EBITDA
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| U.S. Open Ablation | $43.0M | +20.8% |
| U.S. Minimally Invasive Ablation | $5.4M | -27.5% |
| U.S. Pain Management | $28.1M | +34.7% |
| U.S. Appendage Management | $51.6M | +13.5% |
| International Open Ablation | $11.2M | +3.0% |
| International Minimally Invasive Ablation | $1.9M | +2.2% |
| International Pain Management | $2.4M | +17.3% |
| International Appendage Management | $10.9M | +7.0% |
Risk Factors
- Minimally invasive ablation revenue continues to decline as physicians adopt PFA catheters
- Clinical trial outcomes (BoxX-NoAF, LeAAPS) carry binary risk
- Competition from catheter-based technologies could pressure future growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001323885-26-000038 |
| Document: atrc-20261103.htm | 0001323885-26-000038 |
| Document: 0001323885-26-000038-index-headers.html | 0001323885-26-000038 |
| Document: 0001323885-26-000038-index.html | 0001323885-26-000038 |
| Document: 0001323885-26-000038.txt | 0001323885-26-000038 |
| 8-K Data (Synthetic) | 0001323885-26-000038 |
Track record
19 reports on ATRC
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +89.53% at T+60 after the Jun 14, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $55.42 Now $55.31 −0.20% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $55.72 Now $55.31 −0.74% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $57.53 Now $55.31 −3.86% settles Feb 9
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $57.78 Now $55.31 −4.27% settles Feb 5
- Nov 6, 202610d ago Institutional Cluster Bullish 4/10 Entry $58.54 Now $55.31 −5.52% settles Feb 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $61.28 Now $55.31 −9.74% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Viewing Entry $65.53 Now $55.31 −15.60% settles Feb 2
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $61.25 Now $55.31 −9.70% settles Jan 28
- Oct 5, 20266w ago SC 13G/A Neutral 3/10 Entry $56.37 Now $55.31 −1.88% settles Dec 30
- Sep 14, 20269w ago Insider Cluster Neutral 2/10 Entry $56.22 Now $55.31 −1.62% settles Dec 9
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers